Tagged with EDA

Americas Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also…

Egypt While universal health insurance is the talk of the town in Egypt today, private healthcare groups – serving up to 40 percent of the population in both the insurance and out-of-pocket markets – still have an important role to play. This role covers both providing high quality care to their…

Egypt First founded in 2019 as a new regulatory body independent from Egypt’s Ministry of Health, the Egyptian Drug Authority (EDA) has made significant progress over the last three years. Now recognised as one of the MEA region’s leading regulators, the EDA can point to several notable successes in Egypt’s battle…

Egypt Neeraj Mishra of Alameda Healthcare, the largest private healthcare organisation in Egypt, outlines the organisation’s strategy for Egypt and Africa, how – as a provider of private hospitals – it fits into Egypt’s public healthcare transformation plans, as well as its work on digitalisation.   The opportunity is huge for…

Egypt As Egypt moves towards universal healthcare coverage for its 100 million-plus population, the country has become the fastest growing pharma market in the Middle East and Africa region with a value of USD 6.3 billion. Here are some of the key trends to watch in Egypt as identified by local…

Singapore Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to Singapore, where he has spent almost half of his 20-year pharma career, and take on responsibility for the vast Asia-Pacific…

Egypt Takeda Egypt’s Samy Khalil gives an overview of the company’s presence in the country and the fundamentals behind its double-digit growth there, provides his view of the healthcare transformation of the country – both achievements and challenges – and explains why Egypt was added to Takeda’s Access Markets cluster.  …

Indonesia Takeda gets a first approval for QDENGA, its dengue vaccine, which has been given the green light by the Indonesian National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), making it the only dengue vaccine approved in the country for use in individuals aged 6 to…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar, and Takeda’s investment in an IT centre in the Slovak capital, Bratislava. Elsewhere, Pfizer has begun construction on a new…

Switzerland After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment from Takeda. “Switzerland is a globally recognized hotspot for biopharma companies. As such, it naturally attracts investments. Our role is…

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

Italy Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market.   … in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other…